Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Oncogene|December 8, 2015
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclaxR Bajpai, S M Matulis, C Wei, et al.
Blood|May 9, 2001
Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantationE K Waller, H Rosenthal, T W Jones, et al.
Leukemia & Lymphoma|April 28, 2000
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphomaS Lonial, T W Jones, S Devine, et al.
Bone Marrow Transplantation|September 18, 2002
Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donorsI Redei, A A Langston, S Lonial, et al.
Blood|November 11, 1999
Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host diseaseE K Waller, A M Ship, S Mittelstaedt, et al.
Leukemia|November 14, 2013
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patientsA K Nooka, J L Kaufman, S Muppidi, et al.
Oncogene|April 21, 2015
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemiaB T Gaudette, B Dwivedi, K S Chitta, et al.
Bone Marrow Transplantation|July 16, 2008
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphomaS Murali, E Winton, E K Waller, et al.
Bone Marrow Transplantation|October 29, 2013
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donorsA A Langston, J M Prichard, S Muppidi, et al.
Clinical Pharmacology and Therapeutics|November 19, 2016
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple MyelomaX S Xu, X Yan, T Puchalski, et al.
Pageof 4